GlaxoSmithKline (GSK) and Chiromics have partnered to discover classes of small molecules against biological targets.

The collaboration will leverage Chiromics' compound collections of accessible complexity, Chalis, hit recognition algorithm designed for affinity screening.

Chiromics founder David MacMillan and Princeton University chemistry department chairman and professor of chemistry James McDonnell jointly said, "This collaboration further validates that our chemical technology and discovery platform is a potentially valuable gateway to a new set of small molecules for drug discovery."

Chiromics' cascade catalysis, invented at the MacMillan Laboratories at Princeton University, was used to bring the chemical compound collections together.

Using the core chemical technology, cascade catalysis, a set of molecules with high complexity and with preserved drug-like properties, is expected to be developed.